Revelation Biosciences jump on positive data for new kidney diseases drug
25/10/2022 15:37
** Shares of Revelation Biosciences Inc REVB.O surge 94.3%
to 49 cents in early trade
** REVB announces positive results for their drug
"REVTx-300" in a preclinical model of acute and chronic kidney
disease urn:newsml:reuters.com:*:nFWN31Q7N4
** Revelation plans to initiate Phase 1 clinical studies in
the first half of 2023
** More than 24 mln shares traded, 36 times their 25-day
moving avg
** Including session's gain, stock has fallen 95.2% YTD
(Reporting by Sourasis Bose in Bengaluru)
((Sourasis.bose@thomsonreuters.com))